Patent 11041149

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-flash

PTAB activity (1)

AIA trial proceedings — IPR, PGR, CBM — filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced directly from the PTAB Trial API.

1 active
  • IPR2026-00313IPRfiled Mar 23, 2026vs. Merck Sharp & Dohme LLCPending

Cached for 24 hours. Status strings are sourced verbatim from the PTAB API; the colored badge is our heuristic classification.

Cases on file (2)

Group view →

Specific litigation cases in our database that name US patent 11041149. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

Here's a summary of known litigation involving US patent 11041149:

1. District Court Case: Patent Infringement Lawsuit

  • Plaintiff(s): Halozyme, Inc.
  • Defendant(s): Merck Sharp & Dohme Corp. (now Merck Sharp and Dohme LLC)
  • Jurisdiction: U.S. District Court in New Jersey
  • Case Number: 2:25-cv-03179 (ES) (JRA)
  • Filing Date: April 24, 2025
  • Current Status: Ongoing. Halozyme alleges that Merck's subcutaneous (SC) formulation of KEYTRUDA® (pembrolizumab), marketed as QLEX, infringes 15 of Halozyme's patents, including US 11041149, which cover modified human hyaluronidase PH20 enzymes (MDASE™ technology). Halozyme is seeking damages and injunctive relief to block the commercialization of SC Keytruda. Halozyme has also alleged willful infringement, which could lead to enhanced damages and attorney's fees. Merck has been substituted as Merck Sharp and Dohme LLC.

2. PTAB Case: Inter Partes Review (IPR)

  • Trial Number: IPR2026-00313
  • Patent Number: 11041149
  • Petitioner: Not explicitly stated in the provided snippets for this specific IPR, but generally, in an IPR, the petitioner challenges the patent.
  • Patent Owner/Respondent: Not explicitly stated in the provided snippets for this specific IPR, but the patent owner is Halozyme, Inc. or Halozyme Therapeutics Inc.
  • Filing Date: March 23, 2026
  • Current Status: Pending.

Generated 5/29/2026, 5:54:11 PM